Affiliation:
1. Fifth Affiliated Hospital of Zhengzhou University
Abstract
Abstract
Background: Ferroptosis, an iron-dependent form of regulated cell death driven by excessive lipid peroxidation, has been implicated in the development and therapeutic responses of cancer. However, the role of ferroptosis-related gene profiles in LSCCremains largely unknown. This study aims to identify the prognostic roles of ferroptosis-related genes in LSCC.
Methods: We analyzed sequencing data from the Cancer Genome Atlas and identified ferroptosis-related gene expressionbetween tumors and para‐tumors. We also assessed the prognostic role of these genes using Kaplan–Meier analysis and univariable and multivariable Cox proportional hazards regression model analyses. Immunological correlation, tumor stemness, and drug sensitivity and the transcriptional differences of HSPA5 were also analyzed in LSCC. Then, we investigated the expression of HSPA5 usingimmunohistochemistry in 100 patients with metastatic LSCC and assessed the clinical significance of these markers with different risk factors.
Results: Of the 22 ferroptosis-related genes, the expression of HSPA5, HSPB1, GPX4, FANCD2, CISD1, FDFT1, NFE2L2, SLC1A5, RPL8, NCOA4, TFRC, and SLC7A11 was significantly increased in LSCC compared to adjacent tissues. However, only high expression of HSPA5 can predict progression-free survival (PFS) and disease-free survival time (DFS) in LSCC. Although HSPA5 was also significantly elevated in patients with lung adenocarcinoma, HSPA5 expression did not predict the prognosis of lung adenocarcinoma patients. Notably, higher expression of HSPA5 showed higher responses to chemotherapy but not immunotherapy. Interestingly, HSPA5 expression positively correlated with ferroptosis, cellular responses to hypoxia, tumor proliferation signature, G2M checkpoint, MYC targets, and TGFB. IHC analysis also confirm the increased expression of HSPA5 in metastatic LSCC patients in our cohort. And higher expression of HSPA5 in metastatic LSCC patients demonstrated shorter PFS and overall survival time (OS).
Conclusions: This study shows that ferroptosis-related gene HSPA5 expression is a negative prognostic marker for LSCC.
Publisher
Research Square Platform LLC
Reference56 articles.
1. Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med [Internet]. 2021;27:1345–56. Available from: https://doi.org/10.1038/s41591-021-01450-2.
2. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study;Fitzmaurice C;JAMA Oncol,2017
3. Chaft JE, Rimner A, Weder W, Azzoli CG, Kris MG, Cascone T. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol [Internet]. 2021;18:547–57. Available from: https://doi.org/10.1038/s41571-021-00501-4.
4. Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer;Li BT;N Engl J Med United States,2022
5. Sezer A, Kilickap S, Gümüş M, Bondarenko I, Özgüroğlu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet [Internet]. 2021;397:592–604. Available from: https://www.sciencedirect.com/science/article/pii/S0140673621002282.